TRCT
HUMA icon

Tower Research Capital (TRC)’s Humacyte HUMA Stock Holding History

Tower Research Capital (TRC)’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31K Buy
39,682
+4,732
+14% +$4.38K ﹤0.01% 3154
2026
Q1 		$21.2K Buy
34,950
+24,132
+223% +$25.1K ﹤0.01% 3444
2025
Q4 		$10.4K Sell
10,818
-1,133
-9% -$1.6K ﹤0.01% 3781
2025
Q3 		$20.8K Sell
11,951
-5,567
-32% -$10.9K ﹤0.01% 3276
2025
Q2 		$36.6K Buy
17,518
+7,078
+68% +$13.6K ﹤0.01% 3234
2025
Q1 		$17.8K Buy
10,440
+7,599
+267% +$28.5K ﹤0.01% 3089
2024
Q4 		$14.3K Sell
2,841
-12,006
-81% -$59.4K ﹤0.01% 3465
2024
Q3 		$80.8K Sell
14,847
-13,065
-47% -$86.1K ﹤0.01% 2398
2024
Q2 		$134K Buy
27,912
+22,217
+390% +$116K ﹤0.01% 2371
2024
Q1 		$17.7K Sell
5,695
-3,294
-37% -$11.1K ﹤0.01% 3104
2023
Q4 		$25.5K Buy
8,989
+6,504
+262% +$16.7K ﹤0.01% 3507
2023
Q3 		$7.28K Sell
2,485
-8,961
-78% -$29.6K ﹤0.01% 4483
2023
Q2 		$32.7K Buy
11,446
+6,821
+147% +$24.6K ﹤0.01% 2947
2023
Q1 		$14K Buy
4,625
+80
+2% +$227 ﹤0.01% 3886
2022
Q4 		$9K Buy
4,545
+557
+14% +$1.69K ﹤0.01% 4203
2022
Q3 		$13K Sell
3,988
-2,707
-40% -$10.4K ﹤0.01% 4269
2022
Q2 		$21K Buy
6,695
+2,516
+60% +$14K ﹤0.01% 3740
2022
Q1 		$30K Sell
4,179
-381
-8% -$2.22K ﹤0.01% 3148
2021
Q4 		$33K Buy
+4,560
New +$45.1K ﹤0.01% 3130

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tower Research Capital (TRC)'s HUMA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Humacyte (HUMA) stake by 14% in Q2 2026, buying an estimated $4.38K and bringing the position to 39,682 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Tower Research Capital (TRC) first reported a position in HUMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $134K in Q2 2024. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Tower Research Capital (TRC) held 39,682 shares of Humacyte worth $31K as of Q2 2026.
  • Tower Research Capital (TRC) bought 4,732 Humacyte shares in Q2 2026, an estimated $4.38K.
  • Humacyte made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3154 holding.
  • Tower Research Capital (TRC) first reported a position in Humacyte in Q4 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Humacyte position peaked at $134K in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.